Article Text

Download PDFPDF

  1. S. A. A. Tabra1,
  2. M. H. Abu-Zaid1,
  3. S. Hablas1
  1. 1Faculty of Medicine Tanta University, Rheumatology and Rehabilitation, Tanta, Egypt


Background: Fibromyalgia syndrome (FMS) is a chronic pain syndrome which presented by easy fatigability, widespread body pain, anxiety and tenderness points on specific anatomic regions. Fibromyalgia may be risk factor for vitamin D deficiency because of pain, poor mobility, or depression, potentially leading to less time of sun exposure or high rates of adiposity leading to decreased synthesis of vitamin D & there are conflicting results on the role of vitamin D in improving chronic nonspecific musculoskeletal pains1, 2.

Objectives: Assessment of the effectiveness of vitamin D supplements as adjuvant therapy in functional status, quality of life and psychological status in fibromyalgia patients with vitamin D insufficiency.

Methods: One hundred adult patients of primary FMS (according to the 2010 ACR criteria for FMS) associated with vitamin D insufficiency (21-29 ng/mL) were selected to participate in this study. Patients with secondary FMS were excluded; also we excluded patients with any psychiatric disorders and patients who had other chronic diseases interfering with calcium, phosphorus, and vitamin D metabolism. After written consent; the patients were randomly divided into 2 equal groups; group I received duloxetine (60 mg once daily for 6 months) plus 50,000 unit oral cholecalciferol weekly for 8 weeks then monthly for 16 weeks. Group II received duloxetine (60 mg once daily for 6 months) plus placebo. The patients were assessed at baseline and after 6 months of treatment by measuring serum levels of 25(OH)D, Fibromyalgia Impact Questionnaire (FIQ), Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36) & Hospital Anxiety and Depression Scale (HADS).

Results: Eighty six patients completed this study. There was no significant difference between all groups in demographic data, educational status and all baseline variants except serum levels of 25(OH) D. After 6 months; there was significant improvement (P<0.05) in group I in serum levels of 25(OH) D. There was significant improvement (P<0.05) after 6 months in FIQ, SF-36 and HADS in both groups. There was significant better improvement (P<0.05) in group I than in group II in FIQ, SF-36 and HADS. The results of the study are summarized in table 1.

Table 1.

Pre- and post-treatment assessment measures of the patient groups

Conclusion: Vitamin D supplement is effective as an adjuvant therapy in improving functional status, quality of life and psychological status in fibromyalgia patients with vitamin D insufficiency.

References: [1]Abd Elghany S E et al, Regenerative injection therapy and repetitive transcranial magnetic stimulation in primary fibromyalgia treatment: A comparative study. Journal of Back and Musculoskeletal Rehabilitation -1 (2018) 1–8

[2]Maria Helde-Frankling, Linda Björkhem-Bergman. Vitamin D in Pain Management. Int. J. Mol. Sci. 2017, 18, 2170

Disclosure of Interests: : None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.